NASDAQ
CMRA

Comera Life Sciences Holdings Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Comera Life Sciences Holdings Inc Stock Price

Vitals

Today's Low:
$0.375
Today's High:
$0.4417
Open Price:
$0.4417
52W Low:
$0.37
52W High:
$5.7
Prev. Close:
$0.339
Volume:
103292

Company Statistics

Market Cap.:
$9.15 million
Book Value:
-0.275
Revenue TTM:
$930683
Operating Margin TTM:
-1130.12%
Gross Profit TTM:
$422712
Profit Margin:
0%
Return on Assets TTM:
-165.17%
Return on Equity TTM:
-1134.6%

Company Profile

Comera Life Sciences Holdings Inc had its IPO on 2022-05-19 under the ticker symbol CMRA.

The company operates in the Healthcare sector and Biotechnology industry. Comera Life Sciences Holdings Inc has a staff strength of 12 employees.

Stock update

Shares of Comera Life Sciences Holdings Inc opened at $0.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.38 - $0.44, and closed at $0.38.

This is a +10.62% increase from the previous day's closing price.

A total volume of 103,292 shares were traded at the close of the day’s session.

In the last one week, shares of Comera Life Sciences Holdings Inc have slipped by -27.88%.

Comera Life Sciences Holdings Inc's Key Ratios

Comera Life Sciences Holdings Inc has a market cap of $9.15 million, indicating a price to book ratio of 0 and a price to sales ratio of 43.2823.

In the last 12-months Comera Life Sciences Holdings Inc’s revenue was $930683 with a gross profit of $422712 and an EBITDA of $-10420386. The EBITDA ratio measures Comera Life Sciences Holdings Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Comera Life Sciences Holdings Inc’s operating margin was -1130.12% while its return on assets stood at -165.17% with a return of equity of -1134.6%.

In Q1, Comera Life Sciences Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 312.1%.

Comera Life Sciences Holdings Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Comera Life Sciences Holdings Inc’s profitability.

Comera Life Sciences Holdings Inc stock is trading at a EV to sales ratio of 42.5574 and a EV to EBITDA ratio of -1.3742. Its price to sales ratio in the trailing 12-months stood at 43.2823.

Comera Life Sciences Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$3.00 million
Total Liabilities
$3.36 million
Operating Cash Flow
$0
Capital Expenditure
$88359
Dividend Payout Ratio
0%

Comera Life Sciences Holdings Inc ended 2024 with $3.00 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.00 million while shareholder equity stood at $-5264844.00.

Comera Life Sciences Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $3.36 million in other current liabilities, 1915.00 in common stock, $-37385235.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.54 million and cash and short-term investments were $1.54 million. The company’s total short-term debt was $217,500 while long-term debt stood at $0.

Comera Life Sciences Holdings Inc’s total current assets stands at $2.41 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $248635.00 compared to accounts payable of $1.77 million and inventory worth $0.

In 2024, Comera Life Sciences Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $88359.

Comparatively, Comera Life Sciences Holdings Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.38
52-Week High
$5.7
52-Week Low
$0.37
Analyst Target Price
$

Comera Life Sciences Holdings Inc stock is currently trading at $0.38 per share. It touched a 52-week high of $5.7 and a 52-week low of $5.7. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.58 and 200-day moving average was $0.91 The short ratio stood at 3.51 indicating a short percent outstanding of 0%.

Around 5133.1% of the company’s stock are held by insiders while 268.3% are held by institutions.

Frequently Asked Questions About Comera Life Sciences Holdings Inc

The stock symbol (also called stock or share ticker) of Comera Life Sciences Holdings Inc is CMRA

The IPO of Comera Life Sciences Holdings Inc took place on 2022-05-19

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.1
0.02
+25%
$103.8
-9.25
-8.18%
$285.95
-15.05
-5%
$19.19
-0.37
-1.89%
$826.15
-57.2
-6.48%
$21.99
0.97
+4.61%
Asian Paints Limited (ASIANPAINT)
$3256.85
-2.55
-0.08%
$21.42
-1.01
-4.5%
$1449.05
-53.65
-3.57%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company’s lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Address

12 Gill Street, Woburn, MA, United States, 01801